GW873140 In Combination With Kaletra In HIV Infected Subjects

ViiV Healthcare

Status and phase

Terminated

Phase 2

Conditions

HIV Infection

Infection, Human Immunodeficiency Virus I

Treatments

Drug: GW873140

Drug: Kaletra (lopinavir/ritonavir)

Study type

Interventional

Funder types

Industry

Identifiers

NCT00102778

100136

Details and patient eligibility

About

This study is a 96-week study designed to evaluate the safety and efficacy of GW873140 in combination with Kaletra in HIV infected, untreated subjects.

Full description

A Phase IIb, 96 week, randomized, open-label, multicenter, parallel group, repeat dose study to evaluate the safety, tolerability, pharmacokinetics and antiviral effect of different doses and regimens of GW873140 in combination with Kaletra (lopinavir and ritonavir) in HIV-1 infected antiretroviral therapy naive subjects

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

HIV infected, therapy-naive subjects.
Females must be of either non-childbearing age, or have a negative pregnancy test.
All subjects participating in this study should be counseled on the practice of safe sex using a proven double barrier method of contraception throughout the study.
Screening lab result of plasma HIV-1 RNA greater than or equal to 50,000 copies/mL and CD4 cell count greater than or equal to 100 cells/mm3.
Have CC Chemokine Receptor5-tropic (R5-tropic) or CC Chemokine Receptor5/CXC Chemokine Receptor4-tropic (R5/X4-tropic) virus based on viral tropism test at screening visit.
Be treatment-naive, defined as less than or equal to 2 weeks of treatment with a protease inhibitor (PI) or an nucleoside reverse transcriptase inhibitor/nucleotide reverse transcriptase inhibitor (NRTI/ NtRTI), or less than or equal to 7 days of therapy with a non-nucleoside reverse transcriptase inhibitor (NNRTI).
Prior treatment with any entry inhibitor, attachment inhibitor, or fusion inhibitor (experimental or approved) is not allowed.
Be able to understand and follow with protocol requirements, instructions and protocol-stated restrictions.
Signed and dated written informed consent prior to study entry.

Exclusion criteria

No detection of CXC Receptor4-tropic (X4-tropic) virus only, based on viral tropism test at screening.
No active Class C AIDS-defining illness.
No laboratory abnormalities at screen.
No significant blood loss prior to study start.
No pregnant or breastfeeding women.
Additional qualifying criteria to be determined by the physician.